| 6.11 -0.07 (-1.13%) | 12-05 15:57 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 7.81 | 1-year : | 9.12 |
| Resists | First : | 6.69 | Second : | 7.81 |
| Pivot price | 4.9  |
|||
| Supports | First : | 4.42 | Second : | 3.03 |
| MAs | MA(5) : | 6.06 |
MA(20) : | 4.55 |
| MA(100) : | 6.08 |
MA(250) : | 6.27 |
|
| MACD | MACD : | 0.2 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 87.7 |
D(3) : | 91.9 |
| RSI | RSI(14): 61.6 |
|||
| 52-week | High : | 13.17 | Low : | 2.1 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ CRBP ] has closed below upper band by 17.2%. Bollinger Bands are 145.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 4 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 6.19 - 6.23 | 6.23 - 6.27 |
| Low: | 5.75 - 5.79 | 5.79 - 5.82 |
| Close: | 6.12 - 6.19 | 6.19 - 6.24 |
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an anti-integrin monoclonal antibody (mAb) for the treatment of cancer and fibrosis that inhibits the activation of transforming growth factor ß (TGFß); and CRB-602, an anti-avß6/avß8 mAb that blocks the activation of TGFß for the treatment of fibrotic diseases. The company is also developing cannabinoid receptor type 1 inverse agonist program for the treatment of metabolic disorders, such as obesity, diabetic nephropathy, diabetic retinopathy, and nonalcoholic steatohepatitis; fibrotic diseases, including lung, cardiac, renal disease, and liver fibrosis; and other diseases comprising ascites, cognitive defects, Prader-Willi syndrome, and smoking cessation. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.
Tue, 05 Dec 2023
Corbus Pharmaceuticals Holdings Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Mon, 04 Dec 2023
Corbus Pharmaceuticals Holdings Inc. stock underperforms Monday when compared to competitors - MarketWatch
Fri, 01 Dec 2023
Corbus Pharmaceuticals Holdings Inc. stock falls Friday, underperforms market - MarketWatch
Thu, 30 Nov 2023
Corbus Pharmaceuticals Holdings Inc. stock outperforms market on strong trading day - MarketWatch
Wed, 29 Nov 2023
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch
Tue, 28 Nov 2023
Corbus Pharmaceuticals Holdings Inc. stock falls Tuesday, underperforms market - MarketWatch
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 4 (M) |
| Shares Float | 4 (M) |
| Held by Insiders | 0.3 (%) |
| Held by Institutions | 17.7 (%) |
| Shares Short | 57 (K) |
| Shares Short P.Month | 62 (K) |
| EPS | -11.12 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.07 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -52 % |
| Return on Equity (ttm) | -224.7 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -3.66 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -10.21 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -38 (M) |
| Levered Free Cash Flow | -20 (M) |
| PE Ratio | -0.55 |
| PEG Ratio | 0 |
| Price to Book value | 87.28 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.72 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|